Valeant to re-build European operations with €350 million Swiss acquisition
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals is to acquire PharmaSwiss, a privately-owned branded generics and over-the-counter (OTC) pharmaceutical company, for €350 million.